Multiple sclerosis treatment is one of neurology's biggest success stories, and one of its most unfinished. The first disease modifying therapy arrived only in 1993. Today more than 20 are approved, and people diagnosed with relapsing MS now have options their parents' generation could not imagine. But the progressive forms of MS, where disability grows steadily rather than in attacks, still have almost no approved medicines. One form has exactly one. Another has zero.
Nearly 1 million adults in the US live with MS. This article covers what treatment looks like today, what researchers are testing right now, including a drug that came within one FDA decision of changing the field in 2025, and where clinical trials fit in.
Looking for treatment options for Multiple Sclerosis?
Browse open Multiple Sclerosis clinical trials near you! We'll handle the follow-up.
What MS Treatment Includes Today
MS care works on three levels. First, treating relapses when they happen, usually with steroids. Second, managing symptoms like fatigue and muscle stiffness. And third, the most important part: disease modifying therapies, or DMTs. These are medicines that reduce attacks and slow down damage over the years, not just treat symptoms as they come up.
DMTs come in three forms. Injections were first: interferon beta medicines and glatiramer acetate, the original drugs from the 1990s. Pills came next, including fingolimod, dimethyl fumarate, and teriflunomide. And infusions are the strongest option: drugs like natalizumab (Tysabri) and the anti-CD20 antibodies ocrelizumab (Ocrevus) and ofatumumab (Kesimpta, given as a shot at home), which remove the immune cells (B cells) that cause much of the damage.
Only one drug exists for primary progressive MS. In 2017, ocrelizumab became the first, and still the only, medicine approved for PPMS, the form where disability builds up from the very start. For non-relapsing secondary progressive MS, there's still no approved treatment at all, which makes it one of the most closely watched areas in MS research today.
Doctors are changing how they think about treatment. For years, doctors started patients on milder drugs and only moved to stronger ones if needed. Growing evidence now supports starting with a high-efficacy treatment early, in people with active disease, before damage builds up. Which approach is right for a given person is an individual decision, and several large studies comparing the two strategies head-to-head are still running.
What Researchers Are Studying Now
BTK inhibitors, and the December 2025 plot twist. The most closely watched new drug class is brain-penetrant BTK inhibitor pills. They're designed to reach immune cells inside the brain itself, something today's DMTs mostly can't do. The lead drug, Sanofi's tolebrutinib, slowed disability progression by 31% compared to placebo in the HERCULES trial, which included 1,131 people with non-relapsing secondary progressive MS, a form with zero approved treatments. The FDA gave it breakthrough status, then in December 2025 declined approval and asked for more data. The company is continuing the program, and a Phase 3 study in primary progressive MS is also underway. Whatever happens next, HERCULES proved the target is real: the slow, quiet inflammation inside the brain can actually be treated.
Repairing the nerve coating, not just protecting it. Every approved DMT works by holding back the immune system. A newer line of research tries something different: rebuilding the damaged coating around nerves itself, called remyelination. It's still early, and nothing is approved yet, but it's the clearest path researchers have toward reversing disability, not just slowing it down.
The virus lead. In 2022, researchers found that infection with Epstein-Barr virus raises MS risk 32-fold. Since then, companies have started testing EBV-targeted approaches, from vaccines to T-cell therapies. If MS really does start with a virus, treating or preventing that infection would be a brand new way to fight the disease.
What's recruiting on our platform right now. Roche is running an early-stage study of RO7121932, a new antibody approach for people with MS. The University of Colorado is studying risk factors in adults 18 to 30 with early MS, exactly the age range where the disease tends to start. Not every study tests a drug, either: a trial of a full-body electrostimulation garment is testing a rehabilitation device for people with neurological conditions, and a retinal imaging study is checking whether a simple eye scan can track nerve damage, which could make future trials faster for everyone.
Why MS Research Takes Time
The problem with measuring progression. Relapses are easy to count, so trials for relapsing MS get results relatively fast. Disability progression is slow, so trials in progressive MS have to follow large groups of people for years just to see a difference. That's a big reason why treatments for progressive forms of MS lag about two decades behind.
The "quiet damage" problem. Much of the damage in MS happens quietly between relapses, driven by immune cells that live inside the brain, where most drugs simply can't reach. Measuring that hidden process, and designing drugs that can actually cross into the brain, is the field's biggest scientific challenge right now.
The representation problem. MS was long described as a disease of young white women, and trials were built around that assumption. Research now shows Black Americans have a higher rate of MS than previously believed, and often more severe disease, yet they're still underrepresented in trials. Several current studies are specifically recruiting to close that gap. Here's why diversity in clinical trials matters so much.
Common Myths About MS
"MS means a wheelchair is inevitable."
No. Most people with MS never need one, and with early treatment today, long-term disability rates keep going down. MS isn't considered a fatal disease either. Most people live long lives, with life expectancy only slightly below average, and that gap keeps getting smaller.
"Women with MS can't have children."
Outdated. MS doesn't reduce fertility, pregnancy is generally safe with planning, and relapse risk actually tends to go down during pregnancy. Timing treatment around pregnancy is a real conversation to have with a neurologist, not something that's off the table.
"MS is contagious, or caused by something you did."
Neither is true. You can't catch it, and you can't give it to anyone else. The strongest known trigger is a virus almost everyone carries harmlessly, combined with genetics and environment.
"Nothing can be done for progressive MS."
Mostly outdated, partly true. One drug is approved for primary progressive MS, and the first positive Phase 3 result for non-relapsing secondary progressive MS came out in 2025. Options are still limited, which is exactly why progressive MS trials matter more than almost any other research happening right now.
Types of MS, and What Care Usually Looks Like
At CIS, the first episode, doctors often start a DMT early if scans show high risk, since early treatment delays a second attack. In RRMS, the main work is choosing a DMT and adjusting it if the disease stays active, with stronger options increasingly used first. In SPMS with relapses, several DMTs are still approved, while non-relapsing SPMS currently has none, so care focuses on symptoms and rehabilitation instead. In PPMS, ocrelizumab plus symptom management is the standard approach. This describes what care usually looks like, not a personal recommendation. Your plan belongs to you and your neurologist.
For clinical trials, your MS type plus your EDSS disability score are what actually decide eligibility. Study titles usually say "relapsing forms" or "progressive MS" right up front, so knowing your type lets you filter through studies in minutes.
How to Find an MS Clinical Trial
AllClinicalTrials.com lists MS studies recruiting across the US, from drug trials to imaging, rehabilitation, and observational research. The application takes about 5 minutes: you answer questions about your MS type, disability level, and treatment history, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step.
Two examples currently recruiting on our platform: a Northwestern University study of ublituximab (Briumvi) in early relapsing MS is testing the "start strong early" approach directly, in people newly diagnosed. And for women weighing family planning against their MS treatment, UCSF's PRISMA registry is tracking pregnancy, infant health, and breast milk in people with MS, exactly the kind of real-world data that shapes future treatment guidance.
Three things to have ready: your MS type, your latest EDSS score if you know it, and the list of DMTs you have tried. Those three answers decide eligibility for most MS studies.
Common Questions
What is the most effective treatment for MS? There's no single best answer. High-efficacy therapies, like the anti-CD20 antibodies, cut down relapses the most, but the right choice depends on your MS type, how active your disease is, and how much risk you're comfortable with. Several large trials comparing different treatment strategies are still running right now.
What is the newest treatment for MS? The newest approved drugs are in the anti-CD20 class. The most closely watched drug still in testing, a BTK inhibitor called tolebrutinib, slowed disability progression by 31% in progressive MS, but the FDA sent back a request for more data in December 2025, so it isn't approved yet.
Can MS go into remission? Relapsing MS naturally cycles through periods of remission on its own. On modern DMTs, many people reach a state doctors call "no evidence of disease activity," meaning no relapses, no new damage on scans, and no progression. It's not a cure, and doctors keep monitoring even when things look stable.
Do MS trials use a placebo? For relapsing MS, usually not anymore. New drugs are tested against already-approved treatments instead, since leaving MS completely untreated wouldn't be fair to participants. Placebo-controlled trials still happen where no approved treatment exists yet, like non-relapsing secondary progressive MS, which is also exactly where volunteers are needed most.
See multiple sclerosis clinical trials recruiting now:
Browse open studies, filter by location, and apply in about 5 minutes: Multiple Sclerosis Clinical Trials